January 10, 2017 / 4:53 PM / 7 months ago

BRIEF-Bioinvent's partner ThromboGenics initiates phase II study

Jan 10 (Reuters) - Bioinvent International

* Bioinvent's collaboration partner ThromboGenics initiates phase II study with the drug candidate THR-317

* Says first results are expected during the first quarter of 2018 Further company coverage: (Reporting by Stockholm Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below